Asia Pacific Clinical Trials Supplies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product & Service, Stage, Drug Type, and Application

The Asia Pacific clinical trial supplies market is expected to reach US$ 735.66 million by 2027 from US$ 397.66 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The growth of the market is attributed to key driving factors such as increase in prevalence of chronic diseases, low cost of conducting a clinical trial compared to western region and rise in government initiatives to conduct clinical trials. However, challenges for clinical trials due to negative impact of COVID-19 pandemic are expected to restrain the growth of the market during the forecast years.

The clinical trial is an investigational study that defines whether a medical approach, therapy, or device is effective, safe, and useful for human applications. These studies help to find which therapeutic approach is best for certain diseases. Clinical trial supplies management is necessary for evading overproduction, oversupply, and inventory expiration. With the increasing costs of drug discovery, clinical trial supplies are obtaining more importance. The growing healthcare sector in developing countries of Asia-Pacific creates better opportunities for the clinical trial supplies management market players to expand their business. The huge patient population in these countries is generating demand for more clinical trials. The increasing number of clinical trials conducted in Asia Pacific is ascribed to low operational costs, large patient recruitment potential, growth of contract research organizations (CROs), favorable regulatory environment, and better clinical trials capacity and quality. Increase in incidence of chronic diseases in Asia is a key factor that is likely to contributing to the surge in the number of clinical trials in Asia. Moreover, the clinical trials in Asia cost ~30–40% lower than the US and the EU, as the doctor visits, medical treatments, and procedures are less expensive in Asian countries. Also, higher cost of drug development process in developed countries will help propel market growth.

Since the surge of COVID-19 cases, the pharmaceutical industry is facing a decrease in production capabilities, resulting in drug shortages. Moreover, diversion of resources from drug development to coronavirus treatment is likely to hamper overall productivity of the drug development for a short period of span. Various pharmaceutical companies made decisions to postpone the ongoing clinical trials due to disrupted supply chains and threat of the virus. However, several contract research organizations based in Asia Pacific are engaged in a large number of clinical trials for different therapeutics. The outbreak has forced many CROs to close their manufacturing and development plants to avoid the increase in cases. Thus, the COVID-19 pandemic had a positive as well as negative impact on the Asia Pacific clinical trial supplies market.

In terms of product & service, the Asia Pacific clinical trial supplies market is segmented into manufacturing, packaging & labelling, and logistics & distribution. The logistics & distribution segment held the largest share of the market in 2019; the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on stage, the Asia Pacific clinical trial supplies market is segmented into phase I, phase II, phase III, and bioequivalence studies. The phase III segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period.

In terms of drug type, the Asia Pacific clinical trial supplies market is segmented into small-molecule drugs and biologic drugs. The small-molecule drugs segment held the largest share of the market in 2019, whereas the biologic drugs segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the Asia Pacific clinical trial supplies market has been segmented into oncology, cardiovascular diseases, neurological disorders, respiratory disorders, and others. The oncology segment held the largest share of the market in 2019 and is estimated to register the highest CAGR during the forecast period.

A few of the primary and secondary sources associated with this report on the Asia Pacific clinical trial supplies market are the India Brand Equity Foundation (IBEF), National Institute for Health (NIH), and Association of Clinical Research Organizations (ACRO), among others.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific clinical trial supplies market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific clinical trial supplies market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.